« Return to News | R&D Trends | CROs/Service Providers

CRO QPS acquires Qualitix

Wednesday, March 9, 2011 01:28 PM

QPS, a global GLP/GCP-compliant CRO providing testing services for preclinical and clinical R&D, has acquired a majority interest of Qualitix Clinical Research. Qualitix, a spin-off of Taiwan-based biotech Genovate, is a CRO and site management organization (SMO) with offices in Taiwan and China. Genovate will retain a minority interest in Qualitix, which will be known as QPS-Qualitix Taiwan.

QPS’s areas of expertise include toxicology, DMPK, bioanalytical, translational medicine, early-stage and late-stage clinical research.  Qualitix offers research development services to clients in pharmaceutical, biotechnology and medical device industries engaged in new drug development and phase I-IV multinational clinical trials.

The QPS-Qualitix merger will also involve ownership of a subsidiary corporation called Unitix, an SMO that handles QPS-Qualitix patient recruitment in the region.

"We are very happy to partner with QPS. This partnership will not only allow Qualitix to vertically integrate with QPS for more global exposure and market competitiveness, but also offer complete services from preclinical to clinical to expedite new drug development," said Dr. Jen Chen, CEO of Genovate.

"This expansion in phase I-IV clinical capability dovetails with our recent preclinical facility acquisition here in Taiwan," said Vincent Yen, president and CEO of QPS-Taiwan.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.